Department of Oncology, Hebei General Hospital, Shijiazhuang, Hebei, China; Graduate School of North China University of Science and Technology, Tangshan, Hebei, China.
Department of Oncology, Hebei General Hospital, Shijiazhuang, Hebei, China; Graduate School of Hebei North University, Zhangjiakou, Hebei, China.
Biomed Pharmacother. 2022 Apr;148:112703. doi: 10.1016/j.biopha.2022.112703. Epub 2022 Feb 8.
MiR-16-5p, a member of the miR-16 family, has been reported to be abnormal expression in tumor tissues and blood of tumor patients, and also downregulated in most cancer cell lines. Aberrant expression of miR-16-5p promotes tumor cell proliferation, invasion, metastasis, angiogenesis, and can also affect the treatment sensitivity, such as radiotherapy and chemotherapy. Generally, miR-16-5p plays an anti-tumor role and these diverse functions of miR-16-5p in tumors collectively indicate that miR-16-5p may become an attractive target for novel anticancer therapies and a powerful diagnostic and prognostic biomarker for early tumor detection and population risk screening. Herein we review the role and utilization of miR-16-5p in malignant tumor in detail.
miR-16-5p 是 miR-16 家族的成员,据报道在肿瘤组织和肿瘤患者的血液中表达异常,并且在大多数癌细胞系中下调。miR-16-5p 的异常表达促进肿瘤细胞增殖、侵袭、转移、血管生成,还可以影响治疗敏感性,如放疗和化疗。一般来说,miR-16-5p 发挥抑癌作用,miR-16-5p 在肿瘤中的这些不同功能共同表明,miR-16-5p 可能成为新型抗癌治疗的有吸引力的靶点,也是早期肿瘤检测和人群风险筛查的强大诊断和预后生物标志物。本文详细综述了 miR-16-5p 在恶性肿瘤中的作用和应用。